Study of PD1 and PDL1 Expression in Cutaneous T-Cell Lymphomas

被引：0
|
作者：
Gorenkova, Lilya [1 ]
Mangasarova, Yana [1 ]
Shcherstnev, Andrey [1 ]
Kovrigina, Alla [1 ]
Julhakyan, Hunan [1 ]
Zvonkov, Evgeny [1 ]
机构：
[1] Natl Med Res Ctr Hematol, Moscow, Russia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
TCL; PD-1; PDL-1; cutaneous T-cell lymphoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TCL-177
引用
收藏
页码：S466 / S466
页数：1
相关论文
共 50 条
  • [31] Manipulation of the PD1/PDL1 negative T cell costimulatory pathway in treatment of established experimental autoimmune glomerulonephritis
    Reynolds, J.
    Marsh, O. B.
    Sando, G. S.
    Salama, A. D.
    Pusey, C. D.
    IMMUNOLOGY, 2007, 120 : 35 - 35
  • [32] T cell receptor activation status as biological context for interpreting PD1/PDL1 biomarker measurements.
    Parchment, Ralph E.
    Navas, Tony
    Fino, Kristin
    Fung, Andy
    Cutuli, Facundo
    Wang, Lihua
    Kinders, Robert J.
    Doroshow, James H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [33] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
    Jun Tang
    Jia Xin Yu
    Vanessa M. Hubbard-Lucey
    Svetoslav T. Neftelinov
    Jeffrey P. Hodge
    Yunqing Lin
    Nature Reviews Drug Discovery, 2018, 17 : 854 - 855
  • [34] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
    Tang, Jun
    Yu, Jia Xin
    Lin, Yunqing
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) : 854 - 854
  • [35] NIVOLUMAB EXPERIENCE IN REFRACTORY LYMPHOMA CASES WITH PD1, PDL1 POSITIVITY
    Ince, Dilek
    Kizmazoglu, Deniz
    Cecen, Emre
    Laleoglu, Pelin
    Duran, Basak
    Tufekci, Ozlem
    Demiral, Ayse
    Yilmaz, Sebnem
    Ozer, Erdener
    Aktas, Safiye
    Cetingoz, Riza
    Olgun, Nur
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S554 - S555
  • [36] Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
    Samik Upadhaya
    Svetoslav T. Neftelinov
    Jeffrey Hodge
    Jay Campbell
    Nature Reviews Drug Discovery, 2022, 21 : 482 - 483
  • [37] circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma
    Wang, JunFeng
    Zhao, XuHai
    Wang, YanBo
    Ren, FengHai
    Sun, DaWei
    Yan, YuBo
    Kong, XiangLong
    Bu, JianLong
    Liu, MengFeng
    Xu, ShiDong
    CELL DEATH & DISEASE, 2020, 11 (01)
  • [38] Generation of RNA aptamers for measuring fractional occupancy of PD1 by PDL1
    Veeramani, Suresh
    Fischer, Travis
    Thiel, William H.
    Weiner, George J.
    CANCER RESEARCH, 2022, 82 (12)
  • [39] PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
    Stenehjem, David D.
    Tran, Dao
    Nkrumah, Michael A.
    Gupta, Shilpa
    ONCOTARGETS AND THERAPY, 2018, 11 : 5973 - 5989
  • [40] Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
    Upadhaya, Samik
    Neftelinov, Svetoslav T.
    Hodge, Jeffrey
    Campbell, Jay
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (07) : 482 - 483
12345